Beijing DIAGREAT Biotechnology Co., Ltd. was established in 2013, headquartered in Beijing Economic-Technological Development Area. Rooted in precision medicine, our core team comprises seasoned specialists and PhD researchers across clinical medicine, pharmacy, immunology, clinical laboratory medicine and related disciplines.

DIAGREAT maintains sustained engagement in precision medicine with dedicated layout in AI-assisted medication analytical solutions. Harnessing artificial intelligence algorithms, we underpin evidence-based decision-making for complex pharmacotherapy, delivering robust technical frameworks for individualized clinical medication management, medication safety surveillance and accelerated new drug evaluation. Focused on niche segments of precision medicine, DIAGREAT has constructed an AI-enabled medication analysis architecture powered by self-developed large-scale models. The end-to-end intelligent workflow spanning genetic profiling to blood drug concentration monitoring delivers auxiliary analytical insights to facilitate standardized clinical medication administration.

DIAGREAT specializes in the research and development of innovative detection technologies and products for Therapeutic Drug Monitoring (TDM), namely blood drug concentration monitoring. Grounded in pharmacokinetic fundamentals, TDM deploys high-sensitivity, high-stability analytical methodologies to quantify in-vivo drug concentrations, delineate correlations between drug levels, therapeutic responses and toxicological risks, and inform clinicians in regimen optimization and adjustment as a supplementary clinical reference. DIAGREAT has engineered a comprehensive blood drug concentration quantification system, propelling TDM testing toward intelligence, automation and point-of-care deployment.

DIAGREAT has built a full-spectrum R&D and manufacturing platform for upstream core raw materials dedicated to TDM. The platform covers a complete portfolio of technical modules: targeted small-molecule conjugation, antibody development and production, protein engineering, enzyme engineering, nucleic acid synthesis and modification, primer & probe synthesis, gene synthesis and gene sequencing. We sustain self-reliant R&D and localized supply of upstream core raw materials and proprietary technologies. Up to now, our proprietary technologies have secured 51 authorized patents globally, consisting of 39 domestic invention patents, 6 transnational invention patents granted in the United States and Europe, together with 12 design and utility model patents.

DIAGREAT possesses more than 200 medical device registration certifications, alongside over 180 overseas accreditations including EU CE marking and Brazilian certification. The enterprise has attained ISO9001 and ISO13485 international quality management system certifications. Our flagship diagnostic products are distributed to over 60 countries and regions worldwide, and we provide integrated product and technical support to hundreds of Grade A tertiary hospitals nationwide.